Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
The upside case requires Americas and APAC growth to exceed the group path, more cash to remain after investment, and fewer shares to divide earnings.
The risk is triggered if full-year free cash flow falls below $4.0 billion.
Sell. The report was prepared at $468.38 on September 8, 2026, above Fair value of $266.68 and Potential value of $335.79.3
Capital spending is the key risk because it can leave too little cash for owners. The warning sign is annual free cash flow below $4.0 billion.4
The case can improve if Americas and APAC growth exceeds the group path, more cash remains after investment, and fewer shares divide earnings. These are required conditions, not established trends.
A favorable demand cycle would support regional volumes and utilization. Linde benefits most if Americas and APAC grow faster than the group while margins remain near FY2025 levels.5
Sell because the report-date price stands well above the accepted Fair value and Potential value.3
A favorable demand cycle could lift regional volumes and plant use. The benefit would be stronger if growth improves across Americas and APAC while operating profit remains resilient.5
Sell because the report-date price stands well above the accepted Fair value and Potential value.3
Linde provides health care and life insurance benefits to certain eligible retired employees. These benefits are provided through various insurance companies and healthcare providers. The company does not currently fund its postretirement benefits obligations.
Linde’s operations consist of two major product lines: industrial gases and engineering. Other consists of corporate costs and a few smaller businesses which individually do not meet the quantitative thresholds for separate presentation.
The most damaging combination is slower regional demand, weaker margins, and recurring investment that leaves less cash for owners. That path can weaken earnings and value even when reported profit remains sound.
Linde’s reported profitability and strong conversion of profit into operating cash are business outcomes. They do not establish switching costs, installed-base lock-in, software integration, network effects, or a proven scale advantage.
FY2025 operating income was $8.92 billion, but profitability alone does not identify the structural cause needed to call the advantage durable.4
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($266.68). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $5.4B after modeled capex of $5.3B, with terminal value at 58.8% of . A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
A revenue and earnings beat would strengthen the near-term path, but it would not alone prove that long-run margins or share reductions can persist.
The industry benchmark shows capital spending at 4.1% of revenue and 1.55 times depreciation as of September 1, 2026.
A favorable demand cycle could lift regional sales. If Americas and APAC both grow while their profit contribution holds, group sales and operating profit would rise. Persistence remains conditional rather than established by the FY2025 observations.
A synchronized regional slowdown would reduce sales growth and plant utilization. Americas has the greatest consolidated effect because it generated $15.21 billion of FY2025 revenue.
No long position. The report-date price exceeds Fair value and Potential value, while the rating is Sell. Existing exposure should be reduced rather than increased.3
Use the operating triggers rather than price momentum. A strong quarter does not reverse the Sell view unless revenue, margins, and cash after investment improve together.
The report-date price is above Fair value and Potential value, leaving insufficient valuation support.3
Reduce or exit. Recurring capital spending can leave less cash for owners even when reported earnings remain sound.4
The Sell rating and valuation gap outweigh the case for retaining exposure solely for distributions.
Sell because the report-date price of $468.38 exceeds Fair value of $266.68 and Potential value of $335.79.3
The main downside is capital spending leaving less cash for owners. Upside requires stronger regional growth, more cash after investment, and fewer shares together.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
This path is confirmed if the FY2027 growth floor fails, margins remain below their two-year boundary, or annual free cash flow breaches its stated floor.
If FY2027 consolidated revenue growth falls below 3%, the dated demand anchor fails and the later growth fade begins early.1
Operating margin below 24.5% for two fiscal years would reduce operating profit, earnings, and cash generation.4
Annual free cash flow below $4.0 billion would show that recurring investment is absorbing too much operating cash.4
A cost of equity above 10.1291% would reduce the present value of long-duration cash flows while $28.01 billion of debt remains outstanding.23
A terminal valuation below 16 times earnings would mean investors pay less for each dollar of future profit.3
The five developments that would weaken our investment case.
A breach would weaken the dated demand anchor, reduce sales growth, and materially lower earnings and cash-flow expectations after FY2027.
Current:FY2027 analyst revenue mean: $38.05 billion, dated and retrieved September 9, 2026.
Alert ifBelow 3% year over year in FY2027.
Persistent margin weakness would show poorer price-cost conversion, reducing operating profit, earnings per share, and cash available after investment.
Current:FY2025 operating income was $8.92 billion on $33.99 billion of revenue.
Alert ifBelow 24.5% for two consecutive fiscal years.
The breach would show that reported profit is producing too little cash after investment, reducing owner value despite acceptable earnings.
Current:FY2025 capital spending was $5.26 billion.
Alert ifAnnual free cash flow below $4.0 billion for one full fiscal year.
A breach would reduce consolidated sales and operating profit because Americas contributes materially to FY2025 group revenue and reported segment operating income.
Current:Americas produced $15.21 billion of FY2025 revenue and $4.75 billion of operating income.
Alert if
A breach would reduce revenue attributed to China, Germany, and Other International, weakening the international revenue base included in consolidated sales.
Current:FY2025 attributed revenue was $2.60 billion in China, $2.43 billion in Germany, and $11.26 billion in Other International.
Alert ifProspective monitoring assumption: combined attributed growth below 0% for two consecutive fiscal years.
| Threat | Severity | Timeline | Mitigation |
|---|
| Investors may pay less for each dollar of future earnings if growth slows. The comparable-company range is wide, while Linde trades at 24.51 times forward earnings. | high | Through the long-term valuation horizon | Require sustained earnings growth before assuming that the present valuation premium will persist. |
| Direct price competition could pressure margins, but the supplied comparable set does not prove overlapping contracts or share loss. | medium | Over consecutive contract cycles | Treat peers as valuation checks unless contract overlap and sustained price discounts are verified. |
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
The base path supports $266.68, but the shares remain rated Sell because the earnings path does not close the gap to $468.38 (as of 2026-09-08).
This case depends on the stated regional growth and cash-after-investment conditions. It is disconfirmed if recurring capex or valuation normalization overwhelms the earnings path.
Meeting the FY2027 revenue and diluted-earnings estimates would support the earnings path, but would not validate the years beyond FY2027.
A miss would weaken both the near-term earnings anchor and the cash available to owners, reinforcing the Sell conclusion.
FY2025 reported profit was $6.90 billion and capital spending was $5.26 billion. Capital spending is a direct claim on cash, so it limits the amount left for owners.4
This tests whether dated demand visibility can support sales and earnings beyond the next reporting period.1
Lower margins would reduce operating profit, earnings per share, and cash generated from each dollar of sales.4
This shows whether reported profit leaves enough cash after capital spending to support owners.4
Americas is the largest segment, so persistent weakness would have an outsized effect on consolidated sales and profit.5
A smaller share base can lift earnings per share, but only if repurchases do not weaken cash available after investment.34
| $30.79B |
| $33.36B |
| $32.85B |
| $33.01B |
| $33.99B |
| +2.5% |
| Gross profit | $8.62B | $9.71B | $11.55B | $12.08B | $14.73B | +14.3% |
| Operating income | $4.98B | $5.37B | $8.02B | $8.64B | $8.92B | +15.7% |
| Net income | $3.83B | $4.15B | $6.20B | $6.57B | $6.90B | +15.9% |
| EPS (diluted) | $7.33 | $8.23 | $12.59 | $13.62 | $14.61 | +18.8% |
| EBITDA | $9.89B | $9.94B | $12.29B | $12.92B | $12.95B | +7.0% |
| R&D | $143.0M | $143.0M | $146.0M | $150.0M | $147.0M | +0.7% |
| SG&A | $3.19B | $3.11B | $3.30B | $3.34B | $3.43B | +1.9% |
Reported profit produced strong operating cash, yet FY2025 capital spending reached $5.26 billion. Heavy recurring investment can therefore reduce owner cash even when reported earnings remain sound.4
Share reduction supports per-share results, but the funding burden matters. FY2025 capital spending and the lower share count must be judged together rather than treating buybacks as costless growth.
No multi-period, same-basis return-on-invested-capital series is used to infer a trajectory.
No comparison is stated because the supplied return measure and the 7.6673% WACC do not have a verified common basis.
Operating income was $8.92 billion on $33.99 billion of FY2025 revenue.
The earnings case depends on preserving most of that profitability as revenue growth slows.
Diluted average shares fell from 492.290 million in FY2023 to 472.195 million in FY2025; outstanding shares were 460.980 million on September 9, 2026.
Fewer shares can lift earnings per share, but continued reductions require enough cash after capital spending.
| Revenue | $33,986,000,000 |
|---|---|
| Cost of revenue | $19,260,000,000 |
| Gross profit | $14,726,000,000 |
| Operating expenses | $5,803,000,000 |
| Operating income | $8,923,000,000 |
| Non-operating items and tax | -$2,025,000,000 |
| Net income | $6,898,000,000 |
| Total assets | $86,817,000,000 |
|---|---|
| Cash | $5,056,000,000 |
| Current assets | $13,325,000,000 |
| Total liabilities | $47,076,000,000 |
| Current liabilities | $15,198,000,000 |
| Shareholders’ equity | $39,728,000,000 |
| Net income | $6,898,000,000 |
|---|---|
| Operating inflow | $10,794,000,000 |
| Depreciation and amortization | $3,763,000,000 |
| Stock-based compensation | $133,000,000 |
| Operating cash flow | $10,350,000,000 |
| Operating outflow | $444,000,000 |
| Cash available | $15,331,000,000 |
| Beginning cash | $4,850,000,000 |
| Exchange-rate effect | $131,000,000 |
| Investing outflow | $5,721,000,000 |
| Capex | $5,261,000,000 |
| Other investing activities | $460,000,000 |
| Financing outflow | $4,554,000,000 |
| Net debt issuance | $2,911,000,000 |
| Share repurchases | $4,601,000,000 |
| Dividends paid | $2,811,000,000 |
| Other financing activities | $53,000,000 |
| Ending cash | $5,056,000,000 |
| Investing cash flow | -$5,721,000,000 |
| Financing cash flow | -$4,554,000,000 |
Source: SEC EDGAR · Filed 2026-02-25 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Americas | $15.2B | 44.7% | 5.3% |
| EMEA | $8.5B | 25.2% | 2.4% |
| APAC | $6.7B | 19.6% | 0.4% |
| Engineering | $2.3B | 6.6% | -3.1% |
| Corporate And Other | $1.3B | 3.9% | 4.9% |
Source: SEC EDGAR · Filed 2026-02-25 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| United States | $12.2B | 35.8% | 6% |
| Other International | $11.3B | 33.1% | 3.8% |
| China | $2.6B | 7.7% | -1.8% |
| Germany | $2.4B | 7.2% | -3.1% |
| United Kingdom | $1.5B | 4.4% | -1.9% |
| Mexico | $1.4B | 4.1% | 3.3% |
| Brazil | $1.3B | 3.9% | 4.9% |
| Australia | $1.3B | 3.8% | -4.9% |
Point-in-time financial data used in the 2026-09-09 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $10.5B | $3.4B | $1.5B | $2.8B | $1.3B | $1.5B | $1.1B | $39M | $228M | $856M | — | -$1.8B | -$659M | — | $524M | $528M | $9.5B | 21.3% | — | — | — |
| 2017-12-31 | $11.4B | $3.8B | $1.2B | $3B | $1.7B | $1.3B | $1.2B | $59M | $12M | $901M | — | -$1.3B | -$1.7B | $524M | $617M | $617M | $8.8B | 21.5% | — | — | — |
| 2018-12-31 | $14.8B | $7.1B | $4.4B | $3.7B | $1.8B | $1.9B | $1.8B | $62M | $599M | $1.2B | — | $5.4B | -$5B | $617M | $4.5B | $4.5B | $13.8B | 35.4% | — | — | — |
| 2019-12-31 | $28.2B | $8.1B | $2.3B | $6.2B | $2.5B | $3.7B | $4.7B | $95M | $2.7B | $1.9B | — | $1.2B | -$9B | $4.5B | $2.7B | $2.7B | $12.2B | 10.4% | — | — | — |
| 2020-12-31 | $27.2B | $8.1B | $2.5B | $7.4B | $4B | $3.4B | $4.6B | $133M | $2.5B | $2B | — | -$3B | -$3.3B | $2.7B | $3.8B | $5.8B | $12.9B | 12.2% | — | — | — |
| 2021-12-31 | $30.8B | $9.9B | $3.8B | $9.7B | $6.6B | $3.1B | $4.6B | $128M | $4.6B | $2.2B | — | -$3B | -$7.6B | $3.8B | $2.8B | $2.8B | $13B | 16.2% | — | 4.6% | — |
| 2022-12-31 | $33.4B | $9.9B | $4.1B | $8.9B | $5.7B | $3.2B | $4.2B | $107M | $5.2B | $2.3B | $4.5B | -$3.1B | -$3.1B | $2.8B | $5.4B | $5.4B | $13.8B | 16.1% | — | 6.9% | — |
| 2023-12-31 | $32.9B | $12.3B | $6.2B | $9.3B | $5.5B | $3.8B | $3.8B | $141M | $4B | $2.5B | $1.1B | -$4.7B | -$5.4B | $5.4B | $4.7B | $4.7B | $14.7B | 24.4% | — | 7.7% | — |
| 2024-12-31 | $33B | $12.9B | $6.6B | $9.4B | $4.9B | $4.5B | $3.8B | $160M | $4.5B | $2.7B | $3.2B | -$4.6B | -$4.4B | $4.7B | $4.9B | $4.9B | $17.4B | 26.2% | — | 8.2% | — |
| 2025-12-31 | $34B | $12.9B | $6.9B | $10.4B | $5.1B | $5.3B | $3.8B | $133M | $4.6B | $2.8B | $2.9B | -$5.7B | -$4.6B | $4.9B | $5.1B | $5.1B | $22.5B | 26.3% | — | 7.3% | — |
Linde plc (LIN) trades at 24.5x forward earnings against a peer median of 22.3x. Its EV/EBITDA of 17.4x compares with a peer median of 19.3x. The comparison uses 4 peers: The Sherwin-Williams Company, Ecolab Inc., Newmont Corporation and Air Products and Chemicals Inc., as of 2026-09-08 to 2026-09-09.
| Global revenue diversification | neutral | FY2025 revenue was attributed across the United States, China, Germany, and Other International. This spread provides several demand exposures, but the evidence does not establish how they would offset one another in a downturn. |
Linde enters the cycle with substantial operating profit across Americas, EMEA, and APAC. That regional spread helps against isolated weakness but does not protect against a broad demand slowdown.5
| Why |
|---|
| Any price while the Sell rating remains active | Avoid initiating a long position. | The report-date price of $468.38 exceeds Fair value of $266.68 and Potential value of $335.79. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Value each distinct segment, subtract corporate overhead and net debt, add probability-weighted optionality, and divide by diluted shares.
| $9.18B |
| $9.63B |
| $9.96B |
| $10.26B |
| $10.55B |
| $10.82B |
| $11.08B |
| $11.33B |
| $11.57B |
| $11.80B |
| NOPAT | $7.09B | $7.43B | $7.69B | $7.92B | $8.15B | $8.36B | $8.56B | $8.75B | $8.93B | $9.11B |
| Residual cash after reinvestment policy | $7.09B | $7.43B | $7.69B | $7.92B | $8.15B | $8.36B | $8.56B | $8.75B | $8.93B | $9.11B |
| Revenue growth | 6.8% | 4.8% | 3.5% | 3.0% | 2.8% | 2.6% | 2.4% | 2.2% | 2.1% | 2.0% |
| Operating margin | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% | 25.3% |
| Tax rate | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% | 22.8% |
| Reinvestment rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Terminal growth | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% |
| Ecolab Inc. |
| 29.5x |
| 4.6x |
| 21.1x |
| 22.0% |
| 18.5% |
| NEM | Newmont Corporation | 12.6x | 5.2x | 7.7x | 25.9% | 51.6% |
| APD | Air Products and Chemicals Inc. | 20.6x | 5.3x | 18.7x | 0.0% | 25.5% |
